Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Renal Pelvis and Ureter Urothelial Carcinoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oropharyngeal Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mouth Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Accelerated Phase 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematopoietic and Lymphatic System Neoplasm 1Head and Neck Neoplasms 1Down Syndrome 1Carcinoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1

Interventions

Magnetic Resonance Spectroscopy 10Specimen Handling 9Cisplatin 7pembrolizumab 4Radiation 4Platinum 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Cetuximab 3toripalimab 2cemiplimab 2Interviews as Topic 2Docetaxel 2Chemoradiotherapy 2Carboplatin 2sacituzumab govitecan 1merphos 1ipatasertib 1cobimetinib 1cabozantinib 1X-Rays 1Vemurafenib 1Tretinoin 1Transurethral Resection of Bladder 1Taxes 1Surveys and Questionnaires 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Laryngeal Neoplasms × merphos × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡